129 related articles for article (PubMed ID: 37652547)
1. High Tumor Uptake on
De Rycke O; Perrier M; Ouvrard É; Mennetrey C; Lachachi C; Bando-Delaunay A; Morland D; Goichot B; Taieb D; Walter T; Cadiot G; Cros J; Hentic O; Ruszniewski P; Lebtahi R; Imperiale A; de Mestier L
J Nucl Med; 2023 Nov; 64(11):1699-1705. PubMed ID: 37652547
[TBL] [Abstract][Full Text] [Related]
2. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
4. Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [
Chiaravalloti A; Esposito V; Ursini F; Di Giorgio E; Zinzi M; Calabria F; Cimini A; Schillaci O
Ann Nucl Med; 2019 Jul; 33(7):471-480. PubMed ID: 30949937
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of bone metastases detected by
Deleval N; Pesque L; Dieudonné A; Viry F; Hentic O; Lebtahi R; Ruszniewski P; de Mestier L
Eur Radiol; 2021 Jun; 31(6):4166-4174. PubMed ID: 33247341
[TBL] [Abstract][Full Text] [Related]
6. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
7. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
8. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.
Cazzato RL; Garnon J; Ramamurthy N; Tsoumakidou G; Imperiale A; Namer IJ; Bachellier P; Caudrelier J; Rao P; Koch G; Gangi A
Cardiovasc Intervent Radiol; 2016 Sep; 39(9):1315-21. PubMed ID: 27048487
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
[TBL] [Abstract][Full Text] [Related]
12. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adrenal masses using 18 F-FDOPA PET/CT in patients suspected with pheochromocytoma.
Kim SJ; Park CY; Kwon H; Kim YH
Nucl Med Commun; 2024 Jan; 45(1):86-92. PubMed ID: 37901929
[TBL] [Abstract][Full Text] [Related]
14. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
15. Carbidopa-assisted
Helali M; Addeo P; Heimburger C; Detour J; Goichot B; Bachellier P; Namer IJ; Taïeb D; Imperiale A
Ann Nucl Med; 2016 Nov; 30(9):659-668. PubMed ID: 27485404
[TBL] [Abstract][Full Text] [Related]
16. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
17. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
18. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
19. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
